Common biomarkers that are assessed in cfDNA for cancer surveillance pre-transplant in HCC patients include hotspot mutations of TP53, TERT, CTNNB1, VEGF amplification, copy number variants (CNV), and single nucleotide variants (SNV) [104,105,106,107,108,109,110,111]. This evidence concerns the gene TP53 and hepatocellular carcinoma.